Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 21, 2019
|
| In: |
Oncology letters
Year: 2019, Jahrgang: 17, Heft: 6, Pages: 4891-4900 |
| ISSN: | 1792-1082 |
| DOI: | 10.3892/ol.2019.10153 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.3892/ol.2019.10153 Verlag, Volltext: https://doi.org/10.3892/ol.2019.10153 Verlag, Volltext: http://www.spandidos-publications.com/10.3892/ol.2019.10153/abstract 
|
| Verfasserangaben: | Matthias Villalobos, Piotr Czapiewski, Niels Reinmuth, Jürgen R. Fischer, Stefan Andreas, Cornelius Kortsik, Monika Serke, Martin Wolf, Petra Neuser, Alexander Reuss, Philipp A. Schnabel and Michael Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 166882177X | ||
| 003 | DE-627 | ||
| 005 | 20220816185637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190709s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ol.2019.10153 |2 doi | |
| 035 | |a (DE-627)166882177X | ||
| 035 | |a (DE-599)KXP166882177X | ||
| 035 | |a (OCoLC)1341233365 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Villalobos Bollen, Matthias Americo |d 1974- |e VerfasserIn |0 (DE-588)1078644306 |0 (DE-627)839010133 |0 (DE-576)451580516 |4 aut | |
| 245 | 1 | 0 | |a Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab |c Matthias Villalobos, Piotr Czapiewski, Niels Reinmuth, Jürgen R. Fischer, Stefan Andreas, Cornelius Kortsik, Monika Serke, Martin Wolf, Petra Neuser, Alexander Reuss, Philipp A. Schnabel and Michael Thomas |
| 264 | 1 | |c February 21, 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.01.2020 | ||
| 700 | 1 | |a Czapiewski, Piotr |d 1982- |e VerfasserIn |0 (DE-588)1029049882 |0 (DE-627)732373689 |0 (DE-576)376518979 |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |d 1970- |e VerfasserIn |0 (DE-588)122316592 |0 (DE-627)705858936 |0 (DE-576)293216266 |4 aut | |
| 700 | 1 | |a Fischer, Jürgen |d 1953- |e VerfasserIn |0 (DE-588)133724484 |0 (DE-627)691747725 |0 (DE-576)300052510 |4 aut | |
| 700 | 1 | |a Andreas, Stefan |d 1961- |e VerfasserIn |0 (DE-588)1160883459 |0 (DE-627)102428011X |0 (DE-576)50621740X |4 aut | |
| 700 | 1 | |a Kortsik, Cornelius |d 1956- |e VerfasserIn |0 (DE-588)172210860 |0 (DE-627)697124134 |0 (DE-576)133080676 |4 aut | |
| 700 | 1 | |a Serke, Monika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolf, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neuser, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reuss, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schnabel, Philipp Albert |d 1953-2021 |e VerfasserIn |0 (DE-588)102254960X |0 (DE-627)717000087 |0 (DE-576)16982750X |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology letters |d Athens : Spandidos Publ., 2010 |g 17(2019), 6, Seite 4891-4900 |h Online-Ressource |w (DE-627)635601389 |w (DE-600)2573196-8 |w (DE-576)372066399 |x 1792-1082 |7 nnas |a Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab |
| 773 | 1 | 8 | |g volume:17 |g year:2019 |g number:6 |g pages:4891-4900 |g extent:10 |a Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ol.2019.10153 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.3892/ol.2019.10153 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.spandidos-publications.com/10.3892/ol.2019.10153/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200131 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 12 |y j | ||
| 998 | |g 122316592 |a Reinmuth, Niels |m 122316592:Reinmuth, Niels |d 50000 |e 50000PR122316592 |k 0/50000/ |p 3 | ||
| 998 | |g 1078644306 |a Villalobos Bollen, Matthias Americo |m 1078644306:Villalobos Bollen, Matthias Americo |d 910000 |d 950000 |d 950900 |e 910000PV1078644306 |e 950000PV1078644306 |e 950900PV1078644306 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN166882177X |e 3584002125 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"origin":[{"dateIssuedDisp":"2010-","publisher":"Spandidos Publ.","dateIssuedKey":"2010","publisherPlace":"Athens"}],"part":{"issue":"6","volume":"17","extent":"10","text":"17(2019), 6, Seite 4891-4900","year":"2019","pages":"4891-4900"},"id":{"zdb":["2573196-8"],"issn":["1792-1082"],"eki":["635601389"]},"title":[{"title":"Oncology letters","title_sort":"Oncology letters"}],"disp":"Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumabOncology letters","language":["eng"],"pubHistory":["1.2010 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"635601389","note":["Gesehen am 12.10.2020","Volltext auch als Teil einer Datenbank verfügbar"]}],"recId":"166882177X","physDesc":[{"extent":"10 S."}],"note":["Gesehen am 31.01.2020"],"language":["eng"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"February 21, 2019"}],"id":{"eki":["166882177X"],"doi":["10.3892/ol.2019.10153"]},"person":[{"role":"aut","display":"Villalobos Bollen, Matthias Americo","family":"Villalobos Bollen","given":"Matthias Americo"},{"family":"Czapiewski","display":"Czapiewski, Piotr","role":"aut","given":"Piotr"},{"given":"Niels","role":"aut","display":"Reinmuth, Niels","family":"Reinmuth"},{"family":"Fischer","role":"aut","display":"Fischer, Jürgen","given":"Jürgen"},{"role":"aut","display":"Andreas, Stefan","family":"Andreas","given":"Stefan"},{"family":"Kortsik","display":"Kortsik, Cornelius","role":"aut","given":"Cornelius"},{"display":"Serke, Monika","role":"aut","family":"Serke","given":"Monika"},{"family":"Wolf","display":"Wolf, Martin","role":"aut","given":"Martin"},{"given":"Petra","family":"Neuser","display":"Neuser, Petra","role":"aut"},{"family":"Reuss","role":"aut","display":"Reuss, Alexander","given":"Alexander"},{"display":"Schnabel, Philipp Albert","role":"aut","family":"Schnabel","given":"Philipp Albert"},{"role":"aut","display":"Thomas, Michael","family":"Thomas","given":"Michael"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Matthias Villalobos, Piotr Czapiewski, Niels Reinmuth, Jürgen R. Fischer, Stefan Andreas, Cornelius Kortsik, Monika Serke, Martin Wolf, Petra Neuser, Alexander Reuss, Philipp A. Schnabel and Michael Thomas"]},"title":[{"title":"Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab","title_sort":"Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab"}]} | ||
| SRT | |a VILLALOBOSIMPACTOFEM2120 | ||